drugset
Drugs / AVT06
last change Dec 2025 re-read 2 minutes ago

AVT06

Developed for
wet macular degeneration
Investigated by
Alvotech Swiss AG

Trials 1 · a red edge is where a trial was stopped

today NCT05155293 · Ph 3
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT05155293 Jun 2022 → Nov 2023 wet macular degeneration Alvotech Swiss AG Completed No outcome recorded

Press releases naming this drug 4 releases

DateIssuerRelease
2025-12-19 Teva Branded Pharmaceutical Products R&D, Inc. Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® tevapharm.com ↗
2025-12-19 Teva Branded Pharmaceutical Products R&D, Inc. Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® tevapharm.com ↗
2025-02-18 Teva Branded Pharmaceutical Products R&D, Inc. Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) tevapharm.com ↗
2025-02-18 Teva Branded Pharmaceutical Products R&D, Inc. Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) tevapharm.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AVT06 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05155293 ↗
Route Intravitreal “Patients will receive IVT injections of AVT06” NCT05155293 ↗